Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Status:
Recruiting
Trial end date:
2023-01-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well aspirin and rintatolimod with or without
interferon-alpha 2b work in treating patients with prostate cancer before surgery. Aspirin
may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune
system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b
may improve the body's natural response to infections and may slow tumor growth. It is not
yet known how well rintatolimod, aspirin, and interferon-alpha 2b work in treating patients
with prostate cancer undergoing surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
AIM ImmunoTech Inc. National Cancer Institute (NCI)